Kenneth Galbraith, Zymeworks CEO
May 4, 2022 07:21 AM EDT
People

Days af­ter flag­ging its $773M takeover bid, Zymeworks mi­nor­i­ty share­hold­er adds As­traZeneca on­col­o­gy vet to the crew

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Degra­da­tion start­up rais­es $39M for piv­ot to PRO­TACs and clin­i­cal en­try

Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Ver­tex touts promis­ing first few months of launch for non-opi­oid pain drug Jour­navx

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times